Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: A centre-based study of 17 patients

British Journal of Cancer

Volumn 89, Issue 3, 2003, Pages 460-464

  Bumming P ^a   Andersson, J ^a   Meis Kindblom, J M ^a   Klingenstierna, H ^a   Engstrom K ^a   Stierner, U ^a   Wangberg B ^a   Jansson, S ^a   Ahlman, H ^a   Kindblom, L G ^a   Nilsson, B ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Gastrointestinal stromal tumours; Imatinib; KIT gene; Prognosis; Surgery

Indexed keywords

IMATINIB; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; STEM CELL FACTOR RECEPTOR;

ABDOMINAL BLEEDING; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURGERY; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG UTILIZATION; EDEMA; EXON; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYALINE DEGENERATION; MALE; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; OUTCOMES RESEARCH; PROGNOSIS; SCHOOL CHILD; SEQUENCE ANALYSIS; TUMOR NECROSIS; ADJUVANT THERAPY; GASTROINTESTINAL TUMOR; GENETICS; MIDDLE AGED; PALLIATIVE THERAPY; PATHOLOGY; RISK FACTOR; STROMA CELL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; PALLIATIVE CARE; PIPERAZINES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RISK FACTORS; STROMAL CELLS; TREATMENT OUTCOME;

EID: 0042978501     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600965     Document Type: Article

References (18)

1. Andersson J, Sjögren H, Meis-Kindblom J, Stenman G, Åman P, Kindblom L-G (2002) The complexity of KIT gene mutations and chromosome rearrangements and their clinical correlation in gastrointestinal stromal (pacemaker cell) tumors. Am J Pathol 160: 15-22
2. Cancer Therapy Evaluation Program 1999 Common Toxicity Criteria, version 2.0. Bethesda: National Cancer Institute
3. DeMatteo R, Lewis J, Leung D, Mudan S, Woodruff J, Brennan M (2000) Two hundred gastrointestinal stromal tumors, recurrence patterns and prognostic factors for survival. Ann Surg 231: 51-58
4. Demetri GD, Rankin C, Fletcher C, Benjamin RS, Blanke C, Von Mehren M, Bramwell V, Maki RG, Blum R, Antman K, Baker L, Borden E (2002) Phase III dose-randomized study of imatinib mesylate (Gleevec, STI571) for GIST: intergroup S0033 early results. Proc Am Soc Clin Oncol 21: A1651
5. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ, Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin LH, Weiss SW (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33: 459-465
6. Goldman JM, Melo JV (2001) Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1084-1086
7. Heinrich MC, Blanke CD, Druker BJ, Corless CL (2002a) Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20: 1692-1703
8. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Von Mehren M, McGreevey CL, Wait L, Griffith D, Chen C-J, Haley A, Kiese B, Druker BJ, Roberts P, Eisenberg B, Singer S, Silberman S, Dimitrijevic S, Fletcher CDM, Fletcher JA (2002b) KIT mutational status predicts clinical response to STI571 in patients with metastatic gastrointestinal stromal tumors (GISTs). Proc Am Soc Clin Oncol 21: A6
9. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G, Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577-580
10. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, Silberman S, Capdeville R, Dimitrijevic S, Druker BJ, Demetri GD (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344: 1052-1056
11. Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM (1998) Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol 152: 1259-1269
12. Lasota J, Jasinski M, Sarlomo-Rikala M, Miettinen M (1999) Mutations in exon 11 of c-Kit occur preferentially in malignant versus benign gastrointestinal stromal tumors and do not occur in leiomyomas or leiomyosarcomas. Am J Pathol 154: 53-60
13. Rubin BP, Singer S, Tsao C, Duensing A, Lux ML, Ruiz R, Hibbard MK, Chen CJ, Xiao S, Tuveson DA, Demetri GD, Fletcher CD, Fletcher JA (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61: 8118-8121
14. Sakurai S, Fukasawa T, Chong JM, Tanaka A, Fukayama M (1999) C-kit gene abnormalities in gastrointestinal stromal tumors (tumors of interstitial cells of Cajal). Jpn J Cancer Res 90: 1321-1328
15. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, Matsuda H, Kitamura Y (1999) Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 59: 4297-4300
16. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216
17. Tuveson DA, Willis NA, Jacks T, Griffin JD, Singer S, Fletcher CDM, Fletcher JA, Demetri GD (2001) STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20: 5054-5058
18. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358: 1421-1423